Business Context and Reporting Period
Company: Achieve Life Sciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 22, 2021
Event: Entry into a Material Definitive Agreement involving a contingent convertible debt facility.
Key Financial Metrics and Debt Structure
This filing details a new debt instrument rather than operational financial performance. Key terms include:
- Principal Amount: $15.0 million initial term loan with an option to borrow an additional $10.0 million.
- Lenders: Silicon Valley Bank (SVB) and SVB Innovation Credit Fund VIII, L.P.
- Interest Rate: Floating rate (greater of 2.25% or Prime minus 1.0%) plus 7.0% per annum compounded monthly.
- Maturity Date: December 22, 2023 (extendable to December 22, 2024 upon mutual agreement).
- Collateral: Secured by substantially all assets except intellectual property.
- Conversion Price: $9.34 per share.
- Automatic Conversion Trigger: If the stock closing price equals or exceeds $24.00 for 30 consecutive trading days.
Material Changes and Covenants
The company has incurred a new direct financial obligation. Material restrictions and changes include:
- Dividend Restriction: The company is restricted from paying dividends or making distributions on capital stock, subject to limited exceptions.
- Prepayment Penalties: Early repayment incurs a premium of 125% of the outstanding balance if made within 18 months, or 150% if made after 18 months.
- Acquisition Call Price: If the company repays the loan and consummates an acquisition within 12 months, it must pay an additional amount equal to the difference between the actual repayment and the proceeds the lenders would have received had they converted the debt.
- Registration Rights: A Registration Rights Agreement (RRA) was signed, requiring the company to register shares issued upon conversion, subject to a 7% ownership threshold or Rule 144 compliance.
Guidance, Outlook, and Risks
Management Commentary: The filing does not contain specific management commentary regarding future operational guidance or outlook beyond the terms of the debt agreement.
Risks and Contingencies:
- Dilution Risk: Significant dilution may occur if the stock price reaches the $24.00 trigger or if lenders exercise conversion rights at $9.34.
- Liquidity Constraints: The agreement restricts the company's ability to pay dividends and imposes covenants on additional indebtedness and liens.
- Extension Uncertainty: The maturity extension to 2024 is contingent upon lender approval and internal credit approvals.
Investor Verification Checklist
- Verify the current market price of ACHV relative to the $9.34 conversion price and $24.00 automatic conversion trigger.
- Review the company's cash flow statements to assess the ability to service the monthly cash interest payments.
- Confirm the status of the $10.0 million additional borrowing option and any conditions required to draw it.
- Monitor for any potential acquisitions within 12 months of repayment that could trigger the additional call price provision.
- Check subsequent filings for any amendments to the covenants or the maturity date extension.